checkAd

    DGAP-Adhoc  770  0 Kommentare 4SC AG issues second tranche of convertible notes with a nominal amount of EUR 500,000 to Yorkville


    4SC AG / Key word(s): Corporate Action

    03.09.2014 15:07

    Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
    by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    Publication of an ad hoc release pursuant to Section 15 of the German
    Securities Trading Act (Wertpapierhandelsgesetz, WpHG)

    4SC AG issues second tranche of convertible notes with a nominal amount of
    EUR 500,000 to Yorkville

    Planegg-Martinsried, 3 September 2014 - 4SC AG (Frankfurt, Prime Standard:
    VSC) today announced that it successfully completed the issuance of
    convertible notes with a nominal amount of EUR 500,000.00. 4SC will use the
    proceeds for the further preparation of a planned clinical Phase II study
    with its cancer compound resminostat in the liver cancer indication.

    These convertible notes constitute the second tranche of a total issuance
    of up to EUR 15 million guaranteed by an agreement between YA Global Master
    SPV Ltd. ("Yorkville") and the Company, as announced in an ad hoc release
    dated 12 February 2014. Prior to this, a first tranche of convertible notes
    issued in March 2014 of nominally EUR 500,000.00 was completely converted
    into shares. Following the successful conversion of previously issued
    tranches, 4SC's Management will decide independently on a case-by-case
    basis whether additional tranches will be issued.

    Excluding the pre-emptive rights of existing shareholders, the convertible
    notes will be issued exclusively to Yorkville at a subscription price
    corresponding to 95% of the nominal amount. The notes carry no interest,
    have a term of nine month and may be converted into shares of 4SC by the
    holder of the notes at any time. The conversion price equals the volume
    weighted average trading price of 4SC shares during a five-day period prior
    to the time of conversion, less a 5% discount, but it cannot be lower than
    EUR 1.00.

    Ad hoc ends

    Additional information of the issuer of this release

    About 4SC

    The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
    targeted, small-molecule drugs for treating diseases with high unmet
    medical needs in various cancer and autoimmune indications. These drugs are
    intended to provide innovative treatment options that are more tolerable
    and efficacious than existing therapies, and provide a better quality of
    life. The Company's pipeline comprises promising products that are in
    various stages of clinical development. 4SC's aim is to generate future
    growth and enhance its enterprise value by entering into partnerships with
    pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount
    of 65 employees (55 FTEs) at 30 June 2014. 4SC AG has been listed on the
    Prime Standard of the Frankfurt Stock Exchange since December 2005.

    Cautionary statement regarding forward-looking statements

    This press release contains certain forward-looking statements. Any
    forward-looking statement applies only on the date of this press release.
    By their nature, forward-looking statements are subject to a number of
    known and unknown risks and uncertainties that may or may not occur in the
    future and as a result of which the actual results and performance may
    differ substantially from the expected future results or performance
    expressed or implied in the forward looking statements. No warranties or
    representations are made as to the accuracy, achievement or reasonableness
    of such statements, estimates or projections, and 4SC AG has no obligation
    to update any such information or to correct any inaccuracies herein or
    omission herefrom which may become apparent.

    For more information please visit www.4sc.com or contact:

    4SC AG
    Jochen Orlowski, Corporate Communications & Investor Relations
    jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

    MC Services
    Katja Arnold, Michelle Kremer
    katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

    The Trout Group
    Chad Rubin
    crubin(at)troutgroup.com, Tel.: +1-646-378-2947


    03.09.2014 The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: 4SC AG
    Am Klopferspitz 19a
    82152 Martinsried
    Germany
    Phone: +49 (0)89 7007 63-0
    Fax: +49 (0)89 7007 63-29
    E-mail: public@4sc.com
    Internet: www.4sc.de
    ISIN: DE0005753818
    WKN: 575381
    Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
    in Berlin, Düsseldorf, München, Stuttgart

    End of Announcement DGAP News-Service

    ---------------------------------------------------------------------------



    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    DGAP-Adhoc 4SC AG issues second tranche of convertible notes with a nominal amount of EUR 500,000 to Yorkville 4SC AG / Key word(s): Corporate Action 03.09.2014 15:07 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. …